Carbapenem-Resistant Hypervirulent ST11 Klebsiella Pneumoniae Colonization in Zhejiang, China: an Epidemiological, Genomic and Functional Study

Ping Li,Qiqiang Liang,Wugao Liu,Beiwen Zheng,Lizhang Liu,Wei Wang,Zhijiang Xu,Man Huang,Youjun Feng

DOI: https://doi.org/10.2139/ssrn.3386274

2019-01-01

SSRN Electronic Journal

Abstract:The co-occurrence of hypervirulence and KPC-2 carbapenem resistant phenotypes in a highly-transmissible ST11 clone of Klebsiella pneumoniae has elicited a deep concern from public health and social communities. To address this puzzle, we conducted a large-scale epidemiological, clinical and genomic study of K. pneumonia ST11 clones with both hypervirulence and carbapenam resistance in two tertiary hospitals in Zhejiang Province. The majority of the patients (16/24) were diagnosed to be infected with exclusively carbapenem-resistant K. pneumoniae (CRKP) while eight cases had mixed infections. Consequently, ten death cases were recorded, some of which were due to a failure to respond to antibiotic therapies. We identified two new rare sequence types (ST437 & ST449) to KPC-2-producing CRKP, in addition to the dominant ST11. These clinical isolates of K. pneumoniae are multi-drug resistant, and heterogeneous in virulence factor profiles. Experimental infections of wax moth larvae suggested that they are in various level of hypervirulence. Moreover, we completed full genome sequencing of 23 plasmids comprising 13 rmpA2-positive virulence plasmids and 10 blaKPC-2-harboring resistance plasmids. In addition to the prevalent pLVKP-like virulence plasmid variants (~178kb), we found an unexpected diversity among KPC-2-producing plasmids whose dominant form is IncFII-IncR type (~120kb), rather than the previously-anticipated version of ~170kb. Additionally, we are first to report a novel blaKPC-2-carrying ~9.8kb mini-plasmid, designated pK186-KPC. These findings illustrate a more comprehensive picture of convergence of hypervirulence and carbapenem resistance in ST11 K. pneumoniae, providing extensive genomic insights into the diversity of dominant clones in Zhejiang Province.Funding Statement: This work was supported by National Natural Science Foundation of China (31830001, 31570027 & 81772142, YF and 81873946, MH), and National Key R&D Program of China (2017YFD0500202, YF).Declaration of Interests: The authors declare that no conflict of interest is present.Ethics Approval Statement: Clinical data were recorded and approved by the local ethics committee from both the Second Affiliated Hospital, Zhejiang University School of Medicine (2018-01-F) and the Lishui People’s Hospital (2017-005-01).